---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/37901289.md"
description: "Be mentally prepared for long-term holding. The current valuation is extremely low, but risks still exist. The failure of the pulmonary fibrosis trial could drop it to the 30s or 40s. However, the core vaccine business and cash provide a solid value foundation. If the trial succeeds, it won't stop at 40. The commercial value of breakthrough pulmonary delivery is enormous."
datetime: "2026-01-17T03:59:15.000Z"
locales:
  - [en](https://longbridge.com/en/topics/37901289.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/37901289.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/37901289.md)
author: "[砺身济世](https://longbridge.com/en/profiles/19728405.md)"
---

# Be mentally prepared for long-term holding. The cu…


### Related Stocks

- [ARCT.US](https://longbridge.com/en/quote/ARCT.US.md)
- [CSL.US](https://longbridge.com/en/quote/CSL.US.md)
- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)
- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)